Connecting mutant phenylalanine hydroxylase with phenylketonuria

被引：4
作者：
Yan S. [1 ]
Wu G. [2 ]
机构：
[1] Guangxi Academy of Sciences, Nanning, Guangxi 530007
[2] Computational Mutation Project, DreamSciTech Consulting, Shenzhen, Guangdong 518054, Jiannan Road
来源：
Journal of Clinical Monitoring and Computing | 2008年 / 22卷 / 5期
关键词：
Bayes' law; Cross-impact analysis; Distribution probability; Hyperphenylal aninemia; Mutation; Phenylalanine hydroxylase; Phenylketonuria;
D O I：
10.1007/s10877-008-9139-7
中图分类号：
学科分类号：
摘要：
Objective: The building of a quantitative relationship between genotype and phenotype would be great helpful for better clinical monitoring, diagnosis, prognosis and treatment. As the phenylketonuria is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase, in this study we build a descriptively quantitative relationship between mutant phenylalanine hydroxylase and classifications of phenylketonuria. Methods: The amino-acid distribution probability is used to quantify the phenylalanine hydroxylase and its mutants, the cross-impact analysis is used to couple mutant phenylalanine hydroxylase and classifications of phenylketonuria, and the Bayesian equation is used to compute the probability that the phenylketonuria can be classified under mutations. Results: The results show that the patient has more than 0.9 chance of being phenylketonuria when a new mutation occurs in phenylalanine hydroxylase. Conclusions: The built relationship paves the way for modeling of this type relationship for better clinical monitoring, diagnosis, prognosis and treatment. © Springer Science+Business Media, LLC 2008.
引用
收藏
页码：333 / 342
页数：9
相关论文
共 67 条
[1]  
Chou K.C., Structure bioinformatics and its impact to biomedical science, Curr Med Chem, 11, pp. 2105-2134, (2004)
[2]  
Wu G., Yan S., Randomness in the primary structure of protein: Methods and implications, Mol Biol Today, 3, pp. 55-69, (2002)
[3]  
Wu G., Yan S., Mutation trend of hemagglutinin of influenza A virus: A review from computational mutation viewpoint, Acta Pharmacol Sin, 27, pp. 513-526, (2006)
[4]  
Wu G., Yan S., Lecture Notes On Computational Mutation, (2008)
[5]  
Santos L.L., Magalhaes M.C., Januario J.N., Aguiar M.J.B., Carvalho M.R.S., The time has come: A new scene for PKU, Genet Mol Res, 5, pp. 33-44, (2006)
[6]  
Acosta A., Silva Jr. W., Carvalho T., Gomes M., Zago M.A., Mutations of the phenylalanine hydroxylase (PAH) gene in Brazilian patients with phenylketonuria, Hum Mutat, 17, pp. 122-130, (2001)
[7]  
Christ S.E., Abjorn Folling and the discovery of phenylketonuria, J Hist Neurosci, 12, pp. 44-54, (2003)
[8]  
Perez-Duenas B., Vilaseca M.A., Mas A., Lambruschini N., Artuch R., Gomez L., Pineda J., Gutierrez A., Mila M., Campistol J., Tetrahydrobiopterin responsiveness in patients with phenylketonuria, Clin Biochem, 37, pp. 1083-1090, (2004)
[9]  
National Newborn Screening Report: 2000, (2003)
[10]  
Gjetting T., Petersen M., Guldberg P., Guettler F., Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine, Am J Hum Genet, 68, pp. 1353-1360, (2001)
1234567